Cargando…
Lipidized prolactin-releasing peptide improved glucose tolerance in metabolic syndrome: Koletsky and spontaneously hypertensive rat study
BACKGROUND/OBJECTIVES: Prolactin-releasing peptide (PrRP) has a potential to decrease food intake and ameliorate obesity, but is ineffective after peripheral administration. We have previously shown that our novel lipidized analogs PrRP enhances its stability in the circulation and enables its centr...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5851428/ https://www.ncbi.nlm.nih.gov/pubmed/29339795 http://dx.doi.org/10.1038/s41387-017-0015-8 |
_version_ | 1783306388028522496 |
---|---|
author | Mikulášková, Barbora Holubová, Martina Pražienková, Veronika Zemenová, Jana Hrubá, Lucie Haluzík, Martin Železná, Blanka Kuneš, Jaroslav Maletínská, Lenka |
author_facet | Mikulášková, Barbora Holubová, Martina Pražienková, Veronika Zemenová, Jana Hrubá, Lucie Haluzík, Martin Železná, Blanka Kuneš, Jaroslav Maletínská, Lenka |
author_sort | Mikulášková, Barbora |
collection | PubMed |
description | BACKGROUND/OBJECTIVES: Prolactin-releasing peptide (PrRP) has a potential to decrease food intake and ameliorate obesity, but is ineffective after peripheral administration. We have previously shown that our novel lipidized analogs PrRP enhances its stability in the circulation and enables its central effect after peripheral application. The purpose of this study was to explore if sub-chronic administration of novel PrRP analog palmitoylated in position 11 (palm(11)-PrRP31) to Koletsky-spontaneously hypertensive obese rats (SHROB) could lower body weight and glucose intolerance as well as other metabolic parameters. SUBJECTS/METHODS: The SHROB rats (n = 16) were used for this study and age-matched hypertensive lean SHR littermates (n = 16) served as controls. Palm(11)-PrRP31 was administered intraperitoneally to SHR and SHROB (n = 8) at a dose of 5 mg/kg once-daily for 3 weeks. During the dosing period food intake and body weight were monitored. At the end of the experiment the oral glucose tolerance test was performed; plasma and tissue samples were collected. Thereafter, arterial blood pressure was measured. RESULTS: At the end of the experiment, vehicle-treated SHROB rats showed typical metabolic syndrome parameters, including obesity, glucose intolerance, dyslipidemia, and hypertension. Peripheral treatment with palm(11)-PrRP31 progressively decreased the body weight of SHR rats but not SHROB rats, though glucose tolerance was markedly improved in both strains. Moreover, in SHROB palm(11)-PrRP31 ameliorated the HOMA index, insulin/glucagon ratio, and increased insulin receptor substrate 1 and 2 expression in fat and insulin signaling in the hypothalamus, while it had no effect on blood pressure. CONCLUSIONS: We demonstrated that our new lipidized PrRP analog is capable of improving glucose tolerance in obese SHROB rats after peripheral application, suggesting that its effect on glucose metabolism is independent of leptin signaling and body weight lowering. These data suggest that this analog has the potential to be a compound with both anti-obesity and glucose-lowering properties. |
format | Online Article Text |
id | pubmed-5851428 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-58514282018-03-15 Lipidized prolactin-releasing peptide improved glucose tolerance in metabolic syndrome: Koletsky and spontaneously hypertensive rat study Mikulášková, Barbora Holubová, Martina Pražienková, Veronika Zemenová, Jana Hrubá, Lucie Haluzík, Martin Železná, Blanka Kuneš, Jaroslav Maletínská, Lenka Nutr Diabetes Article BACKGROUND/OBJECTIVES: Prolactin-releasing peptide (PrRP) has a potential to decrease food intake and ameliorate obesity, but is ineffective after peripheral administration. We have previously shown that our novel lipidized analogs PrRP enhances its stability in the circulation and enables its central effect after peripheral application. The purpose of this study was to explore if sub-chronic administration of novel PrRP analog palmitoylated in position 11 (palm(11)-PrRP31) to Koletsky-spontaneously hypertensive obese rats (SHROB) could lower body weight and glucose intolerance as well as other metabolic parameters. SUBJECTS/METHODS: The SHROB rats (n = 16) were used for this study and age-matched hypertensive lean SHR littermates (n = 16) served as controls. Palm(11)-PrRP31 was administered intraperitoneally to SHR and SHROB (n = 8) at a dose of 5 mg/kg once-daily for 3 weeks. During the dosing period food intake and body weight were monitored. At the end of the experiment the oral glucose tolerance test was performed; plasma and tissue samples were collected. Thereafter, arterial blood pressure was measured. RESULTS: At the end of the experiment, vehicle-treated SHROB rats showed typical metabolic syndrome parameters, including obesity, glucose intolerance, dyslipidemia, and hypertension. Peripheral treatment with palm(11)-PrRP31 progressively decreased the body weight of SHR rats but not SHROB rats, though glucose tolerance was markedly improved in both strains. Moreover, in SHROB palm(11)-PrRP31 ameliorated the HOMA index, insulin/glucagon ratio, and increased insulin receptor substrate 1 and 2 expression in fat and insulin signaling in the hypothalamus, while it had no effect on blood pressure. CONCLUSIONS: We demonstrated that our new lipidized PrRP analog is capable of improving glucose tolerance in obese SHROB rats after peripheral application, suggesting that its effect on glucose metabolism is independent of leptin signaling and body weight lowering. These data suggest that this analog has the potential to be a compound with both anti-obesity and glucose-lowering properties. Nature Publishing Group UK 2018-01-16 /pmc/articles/PMC5851428/ /pubmed/29339795 http://dx.doi.org/10.1038/s41387-017-0015-8 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Mikulášková, Barbora Holubová, Martina Pražienková, Veronika Zemenová, Jana Hrubá, Lucie Haluzík, Martin Železná, Blanka Kuneš, Jaroslav Maletínská, Lenka Lipidized prolactin-releasing peptide improved glucose tolerance in metabolic syndrome: Koletsky and spontaneously hypertensive rat study |
title | Lipidized prolactin-releasing peptide improved glucose tolerance in metabolic syndrome: Koletsky and spontaneously hypertensive rat study |
title_full | Lipidized prolactin-releasing peptide improved glucose tolerance in metabolic syndrome: Koletsky and spontaneously hypertensive rat study |
title_fullStr | Lipidized prolactin-releasing peptide improved glucose tolerance in metabolic syndrome: Koletsky and spontaneously hypertensive rat study |
title_full_unstemmed | Lipidized prolactin-releasing peptide improved glucose tolerance in metabolic syndrome: Koletsky and spontaneously hypertensive rat study |
title_short | Lipidized prolactin-releasing peptide improved glucose tolerance in metabolic syndrome: Koletsky and spontaneously hypertensive rat study |
title_sort | lipidized prolactin-releasing peptide improved glucose tolerance in metabolic syndrome: koletsky and spontaneously hypertensive rat study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5851428/ https://www.ncbi.nlm.nih.gov/pubmed/29339795 http://dx.doi.org/10.1038/s41387-017-0015-8 |
work_keys_str_mv | AT mikulaskovabarbora lipidizedprolactinreleasingpeptideimprovedglucosetoleranceinmetabolicsyndromekoletskyandspontaneouslyhypertensiveratstudy AT holubovamartina lipidizedprolactinreleasingpeptideimprovedglucosetoleranceinmetabolicsyndromekoletskyandspontaneouslyhypertensiveratstudy AT prazienkovaveronika lipidizedprolactinreleasingpeptideimprovedglucosetoleranceinmetabolicsyndromekoletskyandspontaneouslyhypertensiveratstudy AT zemenovajana lipidizedprolactinreleasingpeptideimprovedglucosetoleranceinmetabolicsyndromekoletskyandspontaneouslyhypertensiveratstudy AT hrubalucie lipidizedprolactinreleasingpeptideimprovedglucosetoleranceinmetabolicsyndromekoletskyandspontaneouslyhypertensiveratstudy AT haluzikmartin lipidizedprolactinreleasingpeptideimprovedglucosetoleranceinmetabolicsyndromekoletskyandspontaneouslyhypertensiveratstudy AT zeleznablanka lipidizedprolactinreleasingpeptideimprovedglucosetoleranceinmetabolicsyndromekoletskyandspontaneouslyhypertensiveratstudy AT kunesjaroslav lipidizedprolactinreleasingpeptideimprovedglucosetoleranceinmetabolicsyndromekoletskyandspontaneouslyhypertensiveratstudy AT maletinskalenka lipidizedprolactinreleasingpeptideimprovedglucosetoleranceinmetabolicsyndromekoletskyandspontaneouslyhypertensiveratstudy |